Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Denali Therapeutics Inc. is a biopharmaceutical company dedicated to developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage diseases. Their scientific approach is rooted in an understanding of disease biology and a commitment to rigorous therapeutic development. Denali focuses on conditions such as Alzheimer's disease, Parkinson's disease, ALS, and Hunter syndrome (MPS II).
The headquarters serves as the central hub for research and development, clinical operations, corporate administration, and strategic decision-making.
State-of-the-art laboratory facilities for drug discovery and development, modern office spaces designed for collaboration. Located in a biotech campus environment.
Denali fosters a science-driven, innovative, and collaborative work culture. Employees are typically passionate about tackling challenging neurodegenerative diseases and are encouraged to pursue cutting-edge research.
The South San Francisco location places Denali within a rich ecosystem of talent, research institutions, and venture capital, crucial for a biotech company focused on innovation and growth.
Denali Therapeutics primarily operates from its headquarters in South San Francisco, California, which houses its core research, development, and corporate functions. They also maintain an international presence, notably with an office in Zurich, Switzerland (Denali Therapeutics International GmbH), to support global clinical trials, regulatory interactions, and potential commercial activities outside the United States. Their collaborations and clinical trial sites extend their operational reach globally.
161 Oyster Point Blvd
South San Francisco
California
USA
Address: Denali Therapeutics International GmbH, Hardturmstrasse 161, 8005 Zurich, Switzerland
To expand Denali's global reach, manage international clinical studies, and engage with European regulatory bodies and partners.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Denali Therapeutics' leadership includes:
Denali Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Denali has seen some strategic executive appointments and transitions to strengthen its leadership in development and commercialization phases. Notable changes include appointments in late-stage development and commercial roles, reflecting the company's pipeline maturation.
Discover the tools Denali Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Denali Therapeutics primarily uses the email format combining the first initial and last name of the employee, followed by @denalitherapeutics.com. Variations might exist but this is the most common structure.
[first_initial][last]@denalitherapeutics.com
Format
jdoe@denalitherapeutics.com
Example
85%
Success rate
Denali Therapeutics Press Release • May 21, 2024
Denali announced positive interim data from a Phase 1/2 study of DNL126 (SAR443820), an investigational enzyme replacement therapy, showing significant biomarker reductions and safety in Sanfilippo Syndrome Type A patients....more
Denali Therapeutics Press Release • May 7, 2024
Denali reported its Q1 2024 financial results, highlighting progress in its clinical programs, including advancements in Parkinson's, ALS, and MPS II programs, and a strong financial position....more
Denali Therapeutics Press Release • April 2, 2024
Denali announced the dosing of the first participant in a global Phase 2b study of tividenofusp alfa (DNL310) for MPS II (Hunter syndrome), aiming to further evaluate its efficacy and safety....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Denali Therapeutics, are just a search away.